H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $18.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Andrew Fein’s rating is based on Arvinas Holding Company’s promising pipeline developments, particularly with their ARV-102 and ARV-806 programs. The ARV-102 LRRK2 degrader has shown significant progress in penetrating the central nervous system and modulating biomarkers in Parkinson’s patients, which could be further validated by upcoming trials and external studies from Biogen/Denali. This progress suggests a potential de-risking of the entire target class, enhancing the company’s value proposition.
Additionally, the ARV-806 KRAS G12D degrader has demonstrated substantial potency and efficacy in preclinical models, showing over 25-fold potency compared to existing inhibitors and achieving notable tumor regressions. Its ability to synergize with immune checkpoint blockades positions it as a transformative asset in oncology. These developments indicate a strategic shift from focusing on vepdegestrant commercialization to executing a robust pipeline, with ARV-102 poised as a critical near-term catalyst, thereby justifying the Buy rating.
In another report released on November 3, BTIG also maintained a Buy rating on the stock with a $14.00 price target.